Signaturefd, LLC I Teos Therapeutics, Inc. Transaction History

Signaturefd, LLC

$5.2 Billion
Q3 2024

A detailed history of Signaturefd, LLC transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 5,034 shares of ITOS stock, worth $41,429. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,034

Previous 5,147 2.2%

Holding current value

$41,429

Previous $76,000 32.89%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	SELL	$10.09 - $17.97 $1,140 - $2,030	-113 Reduced 2.2%	5,034 $51,000
Q2 2024 Jul 29, 2024	SELL	$10.33 - $18.09 $1,053 - $1,845	-102 Reduced 1.94%	5,147 $76,000
Q1 2024 May 03, 2024	BUY	$9.89 - $13.64 $7,595 - $10,475	768 Added 17.14%	5,249 $71,000
Q4 2023 Jan 31, 2024	BUY	$8.57 - $11.06 $27,981 - $36,110	3,265 Added 268.5%	4,481 $49,000
Q3 2023 Nov 03, 2023	BUY	$10.95 - $14.6 $602 - $803	55 Added 4.74%	1,216 $13,000
Q2 2023 Aug 01, 2023	BUY	$12.93 - $18.05 $11,236 - $15,685	869 Added 297.6%	1,161 $15,000
Q1 2023 Apr 28, 2023	BUY	$13.02 - $22.62 $2,018 - $3,506	155 Added 113.14%	292 $3,000
Q4 2022 Jan 27, 2023	SELL	$17.77 - $21.6 $799 - $972	-45 Reduced 24.73%	137 $2,000
Q3 2022 Nov 08, 2022	BUY	$18.6 - $27.25 $3,124 - $4,578	168 Added 1200.0%	182 $3,000
Q2 2022 Aug 10, 2022	BUY	$16.57 - $35.1 $231 - $491	14 New	14 $0
Q1 2022 May 02, 2022	SELL	$31.92 - $47.45 $159 - $237	-5 Closed	0 $0
Q4 2021 Jan 25, 2022	BUY	$26.23 - $47.86 $131 - $239	5 New	5 $0
Q3 2021 Oct 28, 2021	SELL	$23.91 - $29.58 $717 - $887	-30 Closed	0 $0
Q2 2021 Jul 26, 2021	BUY	$17.9 - $36.1 $537 - $1,083	30 New	30 $1,000

Others Institutions Holding ITOS

# of Institutions

165

Shares Held

36.6M

Call Options Held

1.95M

Put Options Held

374K

View Full List

About iTeos Therapeutics, Inc.

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $293M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

More about ITOS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account